Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
10.1016/j.molmed.2007.04.001 · 2007 · External reference
Targeting angiogenesis in oncology, ophthalmology and beyond
10.1038/s41573-023-00671-z · 2023 · External reference
Controlling escape from angiogenesis inhibitors
10.1038/nrc3366 · 2012 · External reference
The role of VEGF in cancer angiogenesis and tumorigenesis: insights for anti-VEGF therapy
10.1016/j.cyto.2025.156908 · 2025 · External reference
Biomarkers of response and resistance to anti-angiogenic therapy
10.1038/nrclinonc.2009.63 · 2009 · External reference
Vessel pruning or healing: endothelial metabolism as a novel target
10.1080/14728222.2017.1282465 · 2017 · External reference
Exploring the spectrum of VEGF inhibitors' toxicities from systemic to intra-vitreal usage in medical practice
10.3390/cancers16020350 · 2024 · External reference
VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells
10.1242/jcs.259617 · 2022 · External reference
Decrease of proliferative potential and vascular density of giant prolactinoma in patients treated with cabergoline
10.4103/ajns.ajns_16_20 · 2020 · External reference
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
10.1038/s41392-023-01469-6 · 2023 · External reference
Ovarian hyperstimulation syndrome
10.1016/b978-0-12-813209-8.00022-4 · 2019 · External reference
Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate
10.1016/j.xfre.2021.07.003 · 2021 · External reference
DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration
10.1172/jci174199 · 2024 · External reference
The neurotransmitter dopamine modulates vascular permeability in the endothelium
10.1186/1750-2187-3-14 · 2008 · External reference
Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells
10.1073/pnas.1108696108 · 2011 · External reference
Substantial production of dopamine in the human gastrointestinal tract
10.1210/jcem.82.11.4339 · 1997 · External reference
Dopamine receptors: from structure to function
10.1152/physrev.1998.78.1.189 · 1998 · External reference
Effect of dopamine as a vascular endothelial growth factor antagonist on the development of acute lung injury in sepsis patients
10.7759/cureus.64102 · 2024 · External reference
DCE-MRI biomarkers in the clinical evaluation of anti-angiogenic and vascular disrupting agents
10.1038/sj.bjc.6603515 · 2007 · External reference
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction
10.1210/jc.2007-0409 · 2007 · External reference
A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline
10.1210/jc.2018-01071 · 2019 · External reference
A quantitative approach for making go/no-go decisions in drug development
10.1177/009286151104500213 · 2011 · External reference
